About Fibromyalgia
According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, fibromyalgia is a syndrome with an unknown cause and chronic pain and muscle tenderness as the major symptoms. Unlike arthritis, it does not cause joint, muscle or other tissue inflammation. However, fibromyalgia is known to cause impairment of joints, soft tissues, and causes significant pain and fatigue. Fibromyalgia affects women more than men. In the US, the condition affects more than 5 million people aged 18 years and above, of which 80-90% are women. There is no particular diagnostic test for detecting fibromyalgia, and physicians undertake differential diagnosis to check the presence of the syndrome. Currently in the US, only three drugs are approved to treat fibromyalgia. Off-label treatment is a popular option to treat fibromyalgia using analgesics, antidepressants, sedatives, neuroleptics, and muscle relaxants.
Technavio's analysts forecast the global fibromyalgia drugs market to grow at a CAGR of 0.79% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global fibromyalgia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of fibromyalgia.
Based on the chemical class of the drugs used to treat fibromyalgia, the market is segmented as follows:
• Serotonin norepinephrine reuptake inhibitors
• GABA analogs
• Others
Technavio's report, the Global Fibromyalgia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.
This report includes a discussion of the market in the following three regions:
• Americas: The major countries here are the US, Canada, Mexico, and Brazil
• EMEA: The major countries here are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
• APAC: The major countries here are Japan, China, Australia, Singapore, South Korea, and India.
APAC is a major untapped market with many leading vendors in the global fibromyalgia drugs market
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Actavis
• Eli Lilly
• Pfizer
Other Prominent Vendors
• Daiichi Sankyo
• Innovative Med Concepts
• Meda
• Meiji Seika
• Merck Sharp and Dohme
• Switch Biotech
• Theravance
• Tonix
• Zynerba Pharmaceuticals
Key Market Driver
• Unmet Medical Needs
• For a full, detailed list, view our report
Key Market Challenge
• Adverse Events
• For a full, detailed list, view our report
Key Market Trend
• Expected Entry of ""Me-too"" Drugs
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Savella
04.1.2 Cymbalta
04.1.3 Lyrica
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1 Understanding the Disease
07.2 Signs and Symptoms
07.2.1 Pain and Muscle Stiffness
07.2.2 Sleep Disturbances
07.2.3 Fatigue
07.2.4 Chronic Headache
07.2.5 Other Symptoms
07.3 Epidemiology
07.4 Pathophysiology
07.5 Economic Burden
07.6 Novel Therapeutic Approach
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Fibromyalgia Drugs Market in US
08.3.1 Market Overview
08.3.2 Market Size and Forecast
08.4 Fibromyalgia Drugs Market in Europe
08.4.1 Market Overview
08.4.2 Market Size and Forecast
08.5 Five Forces Analysis
09. Market Segmentation by Chemical Class of Drug
09.1 Global Fibromyalgia Drugs Market by Chemical Class of Drug 2014-2019
09.2 Serotonin-norepinephrine Reuptake Inhibitors
09.3 GABA Analogs
09.4 Others
10. Geographical Segmentation
10.1 Global Fibromyalgia Drugs Market by Geography 2014-2019
11. Buying Criteria
12. Pipeline Portfolio
12.1 Key Information on Pipeline Candidates
12.1.1 TNX-102 SL
12.1.2 Lyrica CR
12.1.3 DS-5655
12.1.4 TD-9855
12.1.5 IMC-1
12.1.6 Mirtazapine
12.1.7 Flupirtine
12.1.8 SWT06101
12.1.9 ZYN001
13. Market Growth Drivers
14. Drivers and Their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and Their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Major Vendor Analysis 2014
19.2.1 Pfizer
19.2.2 Eli Lilly
19.2.3 Actavis
19.3 Other and Future Prominent Vendors
20. Key Vendor Analysis
20.1 Actavis
20.1.1 Key Facts
20.1.2 Business Description
20.1.3 Business Segmentation
20.1.4 Business Segmentation by Revenue 2012 and 2013
20.1.5 Sales by Geography
20.1.6 Business Strategy
20.1.7 Key Information
20.1.8 SWOT Analysis
20.2 Eli Lilly
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation by Revenue
20.2.4 Sales by Geography
20.2.5 Business Strategy
20.2.6 Key Information
20.2.7 SWOT Analysis
20.3 Pfizer
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation by Revenue 2014
20.3.4 Business Segmentation by Revenue 2013 and 2014
20.3.5 Geographical Segmentation by Revenue 2014
20.3.6 Business Strategy
20.3.7 Key Developments
20.3.8 SWOT Analysis
21. Other Reports in This Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Epidemiology of Fibromyalgia 2014-2019
Exhibit 3: Pathophysiology of Fibromyalgia
Exhibit 4: Global Fibromyalgia Drugs Market 2014-2019 ($ millions)
Exhibit 5: Global Fibromyalgia Drugs Market: Key Takeaways
Exhibit 6: Fibromyalgia Drugs Market in US 2014-2019 ($ millions)
Exhibit 7: Fibromyalgia Drugs Market in Europe 2014-2019 ($ millions)
Exhibit 8: Global Fibromyalgia Drugs Market by Chemical Class of Drug
Exhibit 9: Global Fibromyalgia Drugs Market by Geography 2014
Exhibit 10: Fibromyalgia: Pipeline Portfolio
Exhibit 11: Major Drivers of Global Fibromyalgia Drugs Market
Exhibit 12: Major Challenges in Global Fibromyalgia Drugs Market
Exhibit 13: Major Trends in Global Fibromyalgia Drugs Market
Exhibit 14: Global Fibromyalgia Drugs Market: Vendor Ranking
Exhibit 15: Pfizer: YoY Global Revenue of Lyrica 2010-2014 ($ millions)
Exhibit 16: Pfizer: Key Takeaways
Exhibit 17: Eli Lilly: YoY Global Revenue of Cymbalta 2010-2014 ($ millions)
Exhibit 18: Eli Lilly: Key Takeaways
Exhibit 19: Actavis: YoY Global Revenue of Savella 2010-2013 ($ millions)
Exhibit 20: Actavis: Key Takeaways
Exhibit 21: Global Fibromyalgia Drugs MarketBusiness Segmentation 2013
Exhibit 22: Global Fibromyalgia Drugs Market Business Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 23: Actavis : Sales by Geography ($ millions)
Exhibit 24: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 25: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 26: Eli Lilly: Sales by Geography 2013
Exhibit 27: Pfizer: Business Segmentation by Revenue 2014
Exhibit 28: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 29: Pfizer: Geographical Segmentation by Revenue 2014
